表紙
市場調查報告書

糖尿病性腎障礙 : 開發平台分析

Diabetic Nephropathy - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 192557
出版日期 內容資訊 英文 269 Pages
訂單完成後即時交付
價格
糖尿病性腎障礙 : 開發平台分析 Diabetic Nephropathy - Pipeline Review, H2 2020
出版日期: 2020年08月31日內容資訊: 英文 269 Pages
簡介

所謂糖尿病性腎障礙,是指由於糖尿病發病造成腎臟的損傷。疾病的主要特徵為蛋白尿,及腎小球過濾率低,高血壓等。在易罹病素質中,有肥胖症和高血壓,高脂肪血、高糖血,抽煙等。可用藥物和改善飲食等緩和症狀。

本報告提供世界各國的糖尿病性腎障礙治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業的簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

糖尿病性腎障礙概要

糖尿病性腎障礙:治療藥的開發

糖尿病性腎障礙:治療藥的評估

糖尿病性腎障礙開發治療藥的企業

藥物簡介

糖尿病性腎障礙治療藥:開發暫停的產品

糖尿病性腎障礙治療藥:開發中止的產品

糖尿病性腎障礙相關產品的開發里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12481IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2020, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 23, 11, 28 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Diabetic Nephropathy - Overview
  • Diabetic Nephropathy - Therapeutics Development
  • Diabetic Nephropathy - Therapeutics Assessment
  • Diabetic Nephropathy - Companies Involved in Therapeutics Development
  • Diabetic Nephropathy - Drug Profiles
  • Diabetic Nephropathy - Dormant Projects
  • Diabetic Nephropathy - Discontinued Products
  • Diabetic Nephropathy - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Diabetic Nephropathy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..3), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
  • Number of Products by Stage and Target, H2 2020 (Contd..2), H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..2), H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Diabetic Nephropathy - Pipeline by Aerpio Pharmaceuticals Inc, H2 2020
  • Diabetic Nephropathy - Pipeline by Aibios Co Ltd, H2 2020
  • Diabetic Nephropathy - Pipeline by Algomedix Inc, H2 2020
  • Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H2 2020
  • Diabetic Nephropathy - Pipeline by APT Therapeutics Inc, H2 2020
  • Diabetic Nephropathy - Dormant Projects, H2 2020
  • Diabetic Nephropathy - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Diabetic Nephropathy - Dormant Projects, H2 2020 (Contd..2), H2 2020
  • Diabetic Nephropathy - Dormant Projects, H2 2020 (Contd..3), H2 2020
  • Diabetic Nephropathy - Dormant Projects, H2 2020 (Contd..4), H2 2020
  • Diabetic Nephropathy - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Diabetic Nephropathy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020